Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma

被引：0
|
作者：
Emilio Bajetta
机构：
[1] E Bajetta is Chief of Medical Oncology,
[2] IRCCS Fondazione 'Istituto Nazionale dei Tumori',undefined
[3] Milan,undefined
[4] Italy.,undefined
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The incidence of the skin malignancy, melanoma, is increasing and it often becomes refractory to common therapies after metastasis. In this Viewpoint the author discusses different therapeutic approaches for metastatic melanoma.
引用
收藏
页码：4 / 5
页数：1
相关论文
共 50 条
  • [41] Toxicity of adjuvant high-dose interferon-α-2b in patients with cutaneous melanoma at high risk of recurrence
    Schachter, J
    Brenner, B
    Fenig, E
    Yahav, J
    Marshak, G
    Sulkes, A
    Gutman, H
    [J]. ONCOLOGY REPORTS, 1999, 6 (06) : 1389 - 1393
  • [42] Patterns of failure in patients with malignant melanoma treated with high-dose interferon-α2b in the adjuvant setting
    Schachter, J
    Brenner, B
    Fenig, E
    Gutman, R
    Sulkes, A
    Gutman, H
    [J]. MELANOMA RESEARCH, 2003, 13 (01) : 93 - 96
  • [43] Adjuvant interferon for stage II melanoma
    Haluska, FG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 3205 - 3206
  • [44] Stage III melanoma and pegylated interferon alfa-2b therapy
    不详
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (08) : 809 - 809
  • [45] Pilot study on interferon alpha-2b toxicity in patients with stage III melanoma.
    Nassif, E
    Sideris, L
    [J]. ANNALES DE CHIRURGIE, 1999, 53 (08): : 690 - 692
  • [46] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [47] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Fotemustine and interferon α2b in metastatic malignant melanoma
    Weichenthal, M
    Mohr, P
    Stephan, U
    Altenhoff, J
    Kowalzick, L
    Marseille, A
    Sarkany, M
    Hossfeld, DK
    Breitbart, EW
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (01) : 55 - 59
  • [49] Fotemustine and interferon α2b in metastatic malignant melanoma
    Michael Weichenthal
    Peter Mohr
    Ulrike Stephan
    Jürgen Altenhoff
    Lutz Kowalzick
    Andrea Marseille
    Marlis Sarkany
    Dieter K. Hossfeld
    Eckhard W. Breitbart
    [J]. Journal of Cancer Research and Clinical Oncology, 1998, 124 : 55 - 59
  • [50] A phase I & II trial of peri-operative adjuvant interleukin-2 and interferon alfa 2b in patients with melanoma
    Zapas, JL
    Elias, EG
    Beam, SL
    Picard, DL
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (01) : S20 - S20
12345